Breath of Life (BOL) Pharma is developing cannabinoid-based drugs to improve patients' health and quality of life with high-quality botanical-derived products.

BOL Pharma cultivates and farms its own proprietary cannabis strains, has state-of-the-art certified labs, and owns a plant and a distribution center.

BOL Pharma addresses the medical cannabis, wellness, and pharmaceutical markets.

The pharmaceutical division has launched a spinoff company, with an inhaler based on a Kindeva drug delivery platform (formerly 3M DDS) for selected pain indications as its core product.

This pressurized metered dose inhaler (pMDI) contains cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for multiple sclerosis-related neuropathic pain (lead indication).

Additional follow-on planned indications include chemotherapy-induced and HIV-induced neuropathic pain.The cannabinoid-based pMDI is a combination product of drug/drug/device and offers an efficient administration route of delivery compared to oral delivery.

Inhalation of THC/CBD avoids irregular gastrointestinal absorption and first-pass hepatic metabolism.

This leads to increased bioavailability and improved pharmacokinetics of THC/CBD (reduction in inactive circulating metabolites, larger fraction of active parent THC/CBD).

It also delivers a rapid, consistent, reproducible dose, and is safe (inhalation may reduce hepatoxicity concerns, as lung absorption bypasses first-pass hepatic metabolism) and easy to use (breath actuated, no special preparation required).

The technology is based on a pharmaceutically well-known inhaler device and is environmentally friendly, using low global-warming-potential propellants.

The IP-protected device (with additional IP generated during clinical development) addresses the need for non-opioid analgesics, with a quick onset of action.